Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million, Strengthening Its Oncology Portfolio
In a strategic move to bolster its oncology portfolio, Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, has announced the acquisition of U.S.-based Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company. The $355 million cash deal is set to enhance Sun Pharma’s presence in the onco-dermatology segment by adding Checkpoint’s FDA-approved cancer drug, UNLOXCYT (cosibelimab-ipdl), to its pipeline.
Acquisition Overview
Sun Pharma will pay an upfront cash consideration of $4.10 per share, representing a 66% premium to Checkpoint’s last closing price of $2.47 on the Nasdaq. Additionally, Checkpoint shareholders are entitled to a contingent value right (CVR) of up to $0.70 per share, contingent upon European regulatory approval of cosibelimab within specified deadlines. This structure brings the maximum potential value per share to $4.80, nearly double Checkpoint’s current trading price.
The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions and regulatory approvals. This acquisition aligns with Sun Pharma’s strategic efforts to expand its oncology and immunotherapy portfolio through targeted acquisitions and collaborations.
Strategic Significance
The acquisition of Checkpoint Therapeutics is a significant step for Sun Pharma in strengthening its onco-dermatology offerings. UNLOXCYT, an anti-PD-L1 therapy, is the first and only FDA-approved treatment specifically for advanced cutaneous squamous cell carcinoma (cSCC). This addition is expected to enhance Sun Pharma’s innovative portfolio in onco-derm therapy and provide patients with a new treatment option for cSCC.
Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, emphasized the strategic fit, stating, “Combining UNLOXCYT, an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma’s global presence means patients with cSCC may soon have access to an important, new treatment option.”
James Oliviero, President and CEO of Checkpoint Therapeutics, echoed similar sentiments, highlighting Sun Pharma’s commitment to expanding access to UNLOXCYT in the U.S., Europe, and other global markets.
Financial Implications
For Checkpoint Therapeutics, the acquisition provides immediate liquidity to its shareholders and eliminates the commercialization execution risk. The company reported minimal revenue of $0.04 million and a net loss of $27.3 million for the nine months ending September 2024. With only $4.7 million in cash against $17.6 million in liabilities as of September 2024, independent commercialization of UNLOXCYT would have been challenging without substantial financing.
The deal structure, including the CVR, adds potential value to the transaction. Checkpoint’s stockholders will receive a non-transferable CVR entitling them to receive up to an additional $0.70 per share if cosibelimab is approved in the EU or key European markets by specific deadlines. This CVR structure provides a financial incentive for Sun Pharma to pursue European regulatory approvals, which could significantly boost the drug’s market penetration in Europe.
Market Reaction
Following the announcement, shares of Checkpoint Therapeutics surged 3.78% to close at $2.47 on the Nasdaq. Meanwhile, Sun Pharma’s stock rose 1.2% to ₹1,643.20 on the BSE on Monday, March 10, reflecting investor optimism about the strategic acquisition.
Sun Pharma’s Financial Performance
Sun Pharma has demonstrated robust financial performance in recent quarters, driven by strong sales in both domestic and international markets. Key financial ratios and metrics include:
| Financial Metric | Value |
|---|---|
| P/E Ratio | 34.45 |
| Price to Sales | 7.64 |
| Gross Margin | 78.16% |
| Operating Margin | 23.8% |
| Net Profit Margin | 22.16% |
| Return on Equity | 16.77% |
| Return on Assets | 8.54% |
| Revenue per Share | ₹215.39 |
| Basic EPS | ₹39.91 |
| Book Value per Share | ₹288.72 |
| Dividend Yield | 0.82% |
| Current Ratio | 2.67 |
| Quick Ratio | 1.92 |
| Total Debt to Equity | 3.71% |
| Inventory Turnover | 1.13 |
| Asset Turnover | 0.6 |
In the third quarter ending December 2024, Sun Pharma reported a 15% increase in consolidated net profit to ₹29.03 billion (approximately $335.3 million), surpassing analysts’ expectations. Sales in India, the company’s largest revenue-generating region, rose 14% to ₹43 billion, accounting for about 31% of total sales. The high-margin global specialty pharmaceutical segment reported a 17.5% jump in sales to $370 million, or 21% of total sales.
Future Outlook
The acquisition of Checkpoint Therapeutics is poised to strengthen Sun Pharma’s position in the oncology market, particularly in the treatment of cSCC. The addition of UNLOXCYT to its portfolio aligns with the company’s strategy to expand its specialty drug offerings and enhance its global footprint in the oncology sector.
As Sun Pharma integrates Checkpoint’s assets and pursues regulatory approvals in Europe, the company is expected to leverage its global commercial infrastructure to accelerate UNLOXCYT’s market penetration. This strategic acquisition underscores Sun Pharma’s commitment to providing innovative therapies to patients worldwide and solid
For more market insights, follow our news.
Stay tuned for more updates and insights on the stock market! For more insights on investing in the Indian stock market, check out resource like MoneyControl, ET, NSE India.
Disclaimer: This blog post is for informational purposes only and should not be considered financial advice. Investors should conduct thorough research and consult with a qualified financial advisor before making any investment decisions.